BRCA1 p.Arg1699Gln
Variant summary
The NM_007294.4(BRCA1):c.5096G>A (p.Arg1699Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a cumulative frequency of 0.0000186 (AC=30) in the gnomAD database across 1,613,816 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.00002. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★★). ClinVar reports functional evidence for this variant: "SCV000043748: (2011) found that expression of human BRCA1 with the R1699Q substitution reduced embryonic stem cell survival and caused upregulation of microRNA-155 (MIR155" and additional evidence is available in ClinVar. A different missense at the same amino acid position has been reported as Pathogenic/Likely Pathogenic in ClinVar: p.R1699L: Likely_pathogenic (ClinVar VariationId 55398, 2 stars) Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.R1699= (synonymous): Likely_benign (ClinVar VariationId 1745302, 1 star); p.R1699= (synonymous): Likely_benign (ClinVar VariationId 873409, 2 stars); p.R1699P: Uncertain_significance (ClinVar VariationId 55397, 3 stars); p.R1699G: unknown significance (ClinVar VariationId 869021); p.R1699= (synonymous): Likely_benign (ClinVar VariationId 55395, 3 stars) This exact variant is established as oncogenic in: CGI (Cancer Genome Interpreter). This exact variant is curated in the UniProt human variants database as Uncertain Significance, associated with Breast-ovarian cancer, familial, susceptibility to, 1 (brovca1); it is also listed as a COSMIC curated somatic variant.
Frequency
Consequence
NM_007294.4 missense
Predictors
Clinical Significance
Conservation
Publications
- BRCA1-related cancer predispositionInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- breast-ovarian cancer, familial, susceptibility to, 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- Fanconi anemia, complementation group SInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae), ClinGen
- pancreatic cancer, susceptibility to, 4Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
Classification according to ACMG Germline Pathogenicity v2019
Our verdict: Pathogenic. The variant received 21 points.
| Apply | Criterion Code & Title / Strength | Rationale / Clinical Context | |
|---|---|---|---|
| PS3Functional studies show damaging effect | Well-established functional study supports damaging effect (PS3); SCV000043748: (2011) found that expression of human BRCA1 with the R1699Q substitution reduced embryonic stem cell survival and caused upregulation of microRNA-155 (MIR155; 609337), which has a role in promoting cell growth and is upregulated in various human cancers. Wildtype BRCA1, but not BRCA1 with the R1699Q substitution, downregulated mouse Mir155 expression by recruiting Hdac2 (605164) to the Mir155 promoter, resulting in deacetylation of histones H2a (see 142720) and H3 (see 601128).; SCV000076803: While the results are somewhat conflicting among the different reports, experimental studies have shown that this missense change can disrupt several functional activities of the BRCA1 protein, including transactivation (PMID: 18036263, 17308087, 11157798), phosphopeptide binding (PMID: 21473589, 15133503, 15133502), and nuclear foci formation (PMID: 18036263). RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (internal data).; SCV000186568: In one functional study, the p.R1699Q alteration was shown to destabilize the BRCT domain of the BRCA1 protein and demonstrated reduced, but not abolished, BRCA1 activity (Lovelock PK et al. Breast Cancer Res. 2007;9:R82). In another functional study analyzing protein expression levels in transfected mouse embryonic stem cells, the p.R1699Q alteration showed an intermediate effect in a cisplatin sensitivity assay and a deleterious effect in a PARP inhibitor assay.; SCV000683252: Functional studies have reported that this variant impairs BRCA1 function in transcription activation, cisplatin and PARP inhibitor sensitivity, and homology-directed DNA repair assays (PMID: 11157798, 30458859, 30765603, 32546644).; SCV000693499: Experimental studies have shown that this missense change can disrupt several functional activities of the BRCA1 protein, including transactivation (PMID: 18036263, 17308087, 11157798), phosphopeptide binding (PMID: 21473589, 15133503, 15133502), and nuclear foci formation (PMID: 18036263).; (+9 more) | ||
| PS4Prevalence increased in affected individuals | Rare variant reported in affected individuals by ≥2 independent ClinVar submitters (PS4_Supporting); 17 ClinVar submitter(s) report the variant in affected individuals; SCV000043748: In a Scandinavian family (LUND488) segregating breast-ovarian cancer (604370), Vallon-Christersson et al.; SCV000076803: This variant has been reported in individuals and families affected with breast and/or ovarian cancer (PMID: 11504767, 12827452, 16683254, 20455026, 24504028, 24728189, 25452441, 28490613). In a large family cohort study, including 67 families in which the probands carried the Arg1699Gln change, this variant was shown to segregate with breast and ovarian cancer (PMID: 22889855).; SCV000186568: This mutation has also been detected in trans with BRCA1 c.181T>G (p.C61G) in an individual diagnosed with breast cancer at age 30 years and a mild Fanconi anemia phenotype lacking chromosome fragility (Keupp K et al. Mol Genet Genomic Med 2019 09;7(9):e863).; SCV000605739: The p.Arg1699Gln variant in BRCA1 has been reported in >60 individuals with BRCA1-associated cancers and segregated with disease in multiple relatives from 30 families (Spurdle 2012, Shimelis 2017, Moghadasi 2018). This variant has been described as having reduced penetrance compared to other disease-causing variants: up to 24% risk of BRCA1-related cancer by age 70 (95% CI, 10% to 40%) for Arg1699Gln carriers vs. 58% (95% CI, 7% to 72%) for Arg1699Trp carriers vs. 4.6% risk for women in the general population (Spurdle 2012, Moghadasi 2018).; SCV000683252: This variant has been detected in over 20 individuals and families affected with breast and ovarian cancer (PMID: 11157798, 11410501, 11504767, 12827452, 24504028, 24728189, 25452441, 27495310, 28283652, 29486991, 30287823, 33471991, 35039564, 37563628). This variant has been reported to have reduced penetrance, conferring intermediate risk for breast and ovarian cancer based on case-control studies, carrier family history, segregation and functional studies (PMID: 16489001, 22889855, 28283652, 28490613, 39488595).; (+13 more) | ||
| PM1Mutational hot spot or critical domain | Missense neighbourhood hotspot (≥2 P/LP within ±8 AA, OR ≥ 5 vs. background) — PM1; In-domain: 0 pathogenic, 0 benign rare missense variants; ±8 AA neighbourhood: 31 pathogenic, 8 benign (OR vs. background: 18.5) | ||
| PM2Absent/extremely low in population databases | Rare in gnomAD for AD/XL gene (popmax AF below threshold) — PM2 Supporting; GnomAD popmax AF = 0.00002 — borderline rare for AD+AR gene (base 0.0001, raised to 0.000118 by highest known P/LP ClinVar AF 0.000118) — PM2 supporting | ||
| PM5Novel missense at known pathogenic residue | Different pathogenic missense at same AA residue in ClinVar (PM5); ClinVar contains a germline Pathogenic/Likely Pathogenic entry at the same amino acid position with a different amino acid change: p.R1699L: Likely_pathogenic (ClinVar VariationId 55398, 2 stars); Other variants at the same amino acid residue (not pathogenic): p.R1699= (synonymous): Likely_benign (ClinVar VariationId 1745302, 1 star); p.R1699= (synonymous): Likely_benign (ClinVar VariationId 873409, 2 stars); p.R1699P: Uncertain_significance (ClinVar VariationId 55397, 3 stars); p.R1699G: unknown significance (ClinVar VariationId 869021); p.R1699= (synonymous): Likely_benign (ClinVar VariationId 55395, 3 stars) | ||
| PP1Cosegregation with disease | ClinVar submission reports cosegregation with disease (PP1); SCV000043748: In a Scandinavian family (LUND488) segregating breast-ovarian cancer (604370), Vallon-Christersson et al.; SCV000076803: In a large family cohort study, including 67 families in which the probands carried the Arg1699Gln change, this variant was shown to segregate with breast and ovarian cancer (PMID: 22889855). It has also been observed to segregate with disease in related individuals.; SCV000186568: In a study comparing phenotype and segregation data from 68 p.R1699Q families to 34 pathogenic BRCA1 p.R1699W kindreds and 243 BRCA1 mutation-free families, results strongly supported p.R1699Q as an intermediate risk allele, conferring an estimated 24% (95% CI: 10-40%) risk of female breast or ovarian cancer by age 70 (Spurdle AB et al. J. Med. Genet. 2012 Aug;49:525-32).; SCV000605739: The p.Arg1699Gln variant in BRCA1 has been reported in >60 individuals with BRCA1-associated cancers and segregated with disease in multiple relatives from 30 families (Spurdle 2012, Shimelis 2017, Moghadasi 2018).; SCV000683252: This variant has been reported to have reduced penetrance, conferring intermediate risk for breast and ovarian cancer based on case-control studies, carrier family history, segregation and functional studies (PMID: 16489001, 22889855, 28283652, 28490613, 39488595). A study of 129 families carrying this variant have shown cumulative risks for this variant by age 70 years are about 20% (95% CI 13% to 32%) for breast cancer and 6% (95% CI 3% to 25%) for ovarian cancer, which are between that for BRCA1 truncating variants and the general population (PMID: 28490613).; (+4 more) | ||
| PP3Computational evidence supports damaging effect | Germline meta computational scorer (REVEL/MetaRNN/BayesDel) predicts damaging effect — moderate evidence (PP3); Splicing verdict: not pathogenic; Germline computational verdict: pathogenic (Moderate) | ||
| PP5Reputable source reports pathogenic | ClinVar ≥3 stars pathogenic — very strong (PP5); ClinVar submissions overwhelmingly pathogenic (≥10 total, ≥80% P/LP, <10% B/LB) — strong (PP5, count-based); ClinVar germline classification: Pathogenic/Likely Pathogenic, 3 star(s). ClinVar submissions strongly and reliably favor pathogenicity (51/53 total P/LP) |
Variant Effect in Transcripts
Automated classification analysis was done for transcript: NM_007294.4. You can select a different transcript below to see updated classification assignments.
RefSeq Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
BRCA1 | MANE Select | c.5096G>A p.Arg1699Gln | missense | Exon 17 of 23 | Prot: NP_009225.1 | |
BRCA1 | c.5162G>A p.Arg1721Gln | missense | Exon 18 of 24 | Prot: NP_001394510.1 | ||
BRCA1 | c.5162G>A p.Arg1721Gln | missense | Exon 18 of 24 | Prot: NP_001394511.1 |
Ensembl Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
BRCA1 | MANE Select | c.5096G>A p.Arg1699Gln | missense | Exon 17 of 23 | Prot: ENSP00000350283 | |
BRCA1 | TSL:1 | c.1784G>A p.Arg595Gln | missense | Exon 17 of 22 | Prot: ENSP00000417148 | |
BRCA1 | TSL:1 | c.569G>A p.Arg190Gln | missense | Exon 5 of 11 | Prot: ENSP00000467329 |
Frequencies
Allele frequencies (AF), counts (AC/AN), homozygotes and coverage
| Source / population | AF | AC | Hom | AN | Coverage |
|---|---|---|---|---|---|
Global population databases 6 sources | |||||
GnomAD3 genomes | AF: 0.0000132 | AC:2 | Hom:0 | AN:152020 | Cov:32 |
GnomAD2 exomes | AF: 0.0000239 | AC:6 | AN:251262 | ||
GnomAD4 exome | AF: 0.0000192 | AC:28 | Hom:0 | AN:1461796 | Cov:31 |
GnomAD4 genome | AF: 0.0000132 | AC:2 | Hom:0 | AN:152020 | Cov:32 |
TOPMed (Bravo) | AF: 0.0000227 | AC:6 | Hom:0 | AN:264690 | |
ALFA (dbGaP/dbSNP Allele Frequency Aggregator) | AF: 0.00 | AC:0 | Hom:0 | AN:137886 | |
Local & regional cohorts 2 sources | |||||
ChinaMAP Phase 1 | AF: 0.0000492 | ||||
ToMMo 61KJPN (+60KJPN MNV) | AF: 0.000155 | AC:19 | Hom:0 | AN:122562 | |
Case/control cohorts
| Cohort | Cases | Controls | ||||
|---|---|---|---|---|---|---|
| AF | AC | AN | AF | AC | AN | |
ASC | 0.000360 * | 4 | 11112 | 0.000341 * | 6 | 17618 |
BipEx | 0.00 | 0 | 28420 | 0.0000693 | 2 | 28844 |
Epi25 | 0.0000238 | 1 | 41958 | 0.0000150 | 1 | 66888 |
SCHEMA | 0.0000530 | 6 | 113134 | 0.0000525 | 10 | 190576 |
ClinVar
Computational Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
AlphaGenome AVI | Pathogenic | 30 | |
AlphaMissense | Pathogenic | 0.73 | |
BayesDel_addAF | Pathogenic | 0.35 | D |
BayesDel_noAF | Pathogenic | 0.42 | |
CADD | Pathogenic | 29 | |
DANN | Pathogenic | 1.0 | |
DEOGEN2 | Benign | 0.39 | T |
Eigen | Pathogenic | 0.87 | |
Eigen_PC | Pathogenic | 0.83 | |
FATHMM_MKL | Uncertain | 0.94 | D |
FuncVEP CTI | Pathogenic | 0.99 | |
GPN-Star LLR | N/A | -7.9 | |
GPN-Star score | N/A | 7.9 | |
LIST_S2 | Pathogenic | 0.99 | D |
M_CAP | Pathogenic | 0.75 | D |
MetaRNN | Pathogenic | 0.84 | D |
MetaSVM | Pathogenic | 0.94 | D |
Mutation Taster | N/A | 1/99 | disease causing (ClinVar) |
MutationAssessor | Pathogenic | 3.2 | M |
PhyloP100 | Uncertain | 4.9 | |
popEVE | Benign | -4.2 | |
PrimateAI | Uncertain | 0.66 | T |
PROVEAN | Uncertain | -3.1 | D |
RBP_binding_hub_radar | N/A | 0.0 | |
RBP_regulation_power_radar | N/A | 1.7 | |
REVEL | Pathogenic | 0.79 | |
Sift | Uncertain | 0.0040 | D |
Sift4G | Uncertain | 0.058 | T |
Varity_R | N/A | 0.97 | |
VESM-3B | Benign | -11 |
Splicing Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
Pangolin (max) | Uncertain | 0.23 | |
Pangolin loss | Uncertain | 0.23 | Position offset: 21 |
SpliceAI score (max) | Benign | 0.15 | Details are displayed if max score is > 0.2 |
Splicevardb | N/A | 0.0 |
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.